Search

Postpartum depression, in many respects, has become a household term. Over the last decade, there has been increasing awareness of the importance of screening for postpartum depression, with increased systematic [...]

The last decade has brought appropriate attention to the high prevalence of postpartum mood and anxiety disorders, with postpartum depression (PPD) constituting the most common complication in modern obstetrics. There [...]

The last decade has brought much attention to the risks of fetal exposure to antidepressant medications, with numerous studies describing the risks of adverse outcomes that range from congenital malformations, [...]

Over the past decade adults have been increasingly diagnosed with attention-deficit hyperactivity disorder, including many women in their childbearing years. Patients with attention-deficit hyperactivity disorder can be successfully treated with [...]

Women typically have been counseled to avoid using psychiatric medications during pregnancy because of either known or unknown risks of prenatal exposure to these medications. But data suggest that pregnancy [...]

The use of benzodiazepines to treat anxiety and insomnia during pregnancy as well as pregnancy associated nausea, has persisted despite concerns dating back to the early 1970s that first-trimester use [...]

Women with postpartum depression are frequently counseled to defer treatment if they are going to breast-feed or they elect not to use antidepressants because they want to breast-feed. Usually, the [...]

Even today, many clinicians mistakenly believe that pregnancy is protective against the development or relapse of depression. That misperception persists despite several studies over the past 6 years demonstrating that [...]

Data on the reproductive safety of certain psychotropics, such as selective serotonin reuptake inhibitors and anti-epileptic drugs, have increased in recent years, but information on the attendant risks of fetal [...]

Two of the agents widely used to treat bipolar illness are established teratogens. Lithium is associated with a 0.05% risk of Ebstein's anomaly, a modest teratogenic effect. Sodium valproate is [...]

Physicians and patients may be alarmed by recent changes to the product labels of the selective serotonin reuptake inhibitors and the selective norepinephrine reuptake inhibitor venlafaxine with respect to their [...]

In April, the National Toxicology Program's Center for the Evaluation of Risks to Human Reproduction, established by the NTP and the National Institute of Environmental Health Sciences, part of the [...]

With increasing recognition and treatment of depression in women during their childbearing years, more patients and their physicians are faced with the dilemma of whether to use antidepressants in pregnancy. [...]

Data on the risk of fetal malformations and adverse peripartum events associated with in utero exposure to antidepressants are reassuring, especially with regard to the tricyclics and some of the [...]

The increasing number of reproductive-age women who are on antidepressants has raised concerns about the potential risks of teratogenicity, pennatal toxicity, and the long-term neurobehavioral sequelae of prenatal exposure to [...]

Eating disorders are highly prevalent in the general population, certainly more so in women, appearing to peak during the childbearing years. While we tend not to see pregnant women with [...]

A common scenario seen on our consultation service is a woman with an anxiety or mood disorder who is stabilized on a drug and who wants to switch to an [...]

Bipolar disorder is a chronic relapsing illness with a deteriorating course over time, particularly if there have been multiple episodes. This creates a bind for women in their reproductive years [...]

Postpartum depression, which has a prevalence of 5%-l0%, is characterized by depressive symptoms similar to those associated with major depression in the general population. Symptoms may begin early after delivery, [...]